A Phase 3 interventional study of tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 23 Years to 53 Years. Per ClinicalTrials.gov, last updated 2019-01-17.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 6th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 7th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 23 Years to 53 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2010.
This study's enrollment of 135 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2010, is one of 7 in phase 3, and was the 7th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
This study's enrollment of 135 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Browse Polycystic Kidney, Autosomal Dominant studies →Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Compared within Polycystic Kidney, Autosomal Dominant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polycystic Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
Drug: tolvaptan
Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
Total Kidney Volume
Measured values of total kidney volume (sum of the volume of the left and right kidneys) during trial period. Twice-daily repeated oral administration of tolvaptan at daily doses of 60 to 120 mg. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
Time frame: Baseline, Month12, Month24, and Month36
Renal Function Test (eGFR)
Estimated glomerular filtration rate calculated by Japanese equation for eGFR during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
Time frame: Baseline, Month12, Month24, and Month36
Renal Function Test (Cys-C)
Measured values of serum cystatin C concentration during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
Time frame: Baseline, Month 12, Month 24, and Month 36
| Milestone | Tolvaptan |
|---|---|
| Started | 135 |
| Completed | 113 |
| Not completed | 22 |
| Withdrew: Adverse event | 4 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Egfr under the withdrawal criteria | 7 |
| Withdrew: No tolerability for the lowest dose | 2 |
Measured values of total kidney volume (sum of the volume of the left and right kidneys) during trial period. Twice-daily repeated oral administration of tolvaptan at daily doses of 60 to 120 mg. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
| mL | Baseline | Month 12 | Month 24 | Month 36 |
|---|---|---|---|---|
| Total Kidney Volume | 1812.38 ± 859.21 | 1878.82 ± 950.60 | 1934.14 ± 926.79 | 2214.28 ± 842.87 |
Estimated glomerular filtration rate calculated by Japanese equation for eGFR during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
| mL/min/1.73 m2 | Baseline | Month 12 | Month 24 | Month 36 |
|---|---|---|---|---|
| Renal Function Test (eGFR) | 61.2 ± 21.7 | 56.3 ± 21.7 | 51.8 ± 20.1 | 43.5 ± 20.3 |
Measured values of serum cystatin C concentration during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.
| mg/L | Baselime | Month 12 | Month 24 | Month 36 |
|---|---|---|---|---|
| Renal Function Test (Cys-C) | 1.016 ± 0.421 | 1.114 ± 0.477 | 1.129 ± 0.466 | 1.281 ± 0.461 |
Collected over Through study completion, 2 to 3 years for major patients. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | 0/135 (0%) | 20/135 (14.8%) | 134/135 (99.3%) |
| Event | Tolvaptan |
|---|---|
| Renal cyst infectionInfections and infestations | 4/135 |
| Renal cyst haemorrhageRenal and urinary disorders | 2/135 |
| Cardiac failure acuteCardiac disorders | 1/135 |
| Angina pectorisCardiac disorders | 1/135 |
| IleusGastrointestinal disorders | 1/135 |
| Umbilical herniasGastrointestinal disorders | 1/135 |
| AppendicitisInfections and infestations | 1/135 |
| SepsisInfections and infestations | 1/135 |
| Hepatic cyst infectionInfections and infestations | 1/135 |
| Ligament ruptureInjury, poisoning and procedural complications | 1/135 |
| Event | Tolvaptan |
|---|---|
| ThirstGeneral disorders | 104/135 |
| NasopharyngitisInfections and infestations | 94/135 |
| PollakiuriaRenal and urinary disorders | 77/135 |
| PolyuriaRenal and urinary disorders | 52/135 |
| Back painMusculoskeletal and connective tissue disorders | 30/135 |
| HyperuricaemiaMetabolism and nutrition disorders | 29/135 |
| HeadacheNervous system disorders | 26/135 |
| DiarrhoeaGastrointestinal disorders | 21/135 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 21/135 |
| InfluenzaInfections and infestations | 20/135 |
| Age, Categorical(Participants) | Tolvaptan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 135 |
| >=65 years | 0 |
| Age, Continuous(years) | Tolvaptan |
|---|---|
| Mean | 42.7 ± 5.9 |
| Sex: Female, Male(Participants) | Tolvaptan |
|---|---|
| Female | 77 |
| Male | 58 |
| Region of Enrollment(participants) | Tolvaptan |
|---|---|
| Japan | 135 |
The record gives a start of Nov 2010, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Co., Ltd. →